<DOC>
	<DOCNO>NCT02963506</DOCNO>
	<brief_summary>This study evaluate efficacy safety different dos bimekizumab subject active Ankylosing Spondylitis ( AS ) .</brief_summary>
	<brief_title>A Multicenter Study Evaluate Efficacy Safety Different Doses Bimekizumab Subjects With Active Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Subject active ankylosing spondylitis ( AS ) , determine document radiologic evidence fulfil Modified New York criterion AS include symptom &gt; =3 month age onset &lt; 45 year Subject moderate severe active disease define follow : 1 . BASDAI score &gt; =4 2 . Spinal pain &gt; =4 0 10 NRS ( Numeric Rating Scale ; BASDAI item 2 ) Subjects must least 1 follow : 1. inadequate response nonsteroidal antiinflammatory drug ( NSAID ) therapy 2. intolerance administration least 1 NSAID 3. contraindication ( ) NSAID therapy Subjects regularly take NSAIDs/COX2 inhibitor part AS therapy require stable dose least 14 day Baseline Subjects take corticosteroid must average daily dose &lt; =10mg/day prednisone equivalent least 14 day Baseline remain stable dose Week 16 Subjects take methotrexate ( MTX ) ( &lt; =25mg/week ) allow continue medication start least 12 week prior Baseline , stable dose least 8 week randomization Subjects take sulfasalazine ( 3grams/day ) hydroxychloroquine ( 400mg per day total ) allow continue medication start least 12 week prior Baseline , stable dose least 8 week randomization Subjects may tumor necrosis factor ( TNF ) inhibitorna√Øve may receive 1 prior TNF inhibitor . Subjects TNF inhibitor previously must : 1. experience inadequate response previous treatment give least 3 month 2. intolerant administration ( eg , side effect/adverse event lead discontinuation ) 3. lost access TNF inhibitor reason Subjects total ankylosis spine , diagnosis inflammatory arthritis eg , rheumatoid arthritis ( RA ) , sarcoidosis , systemic lupus erythematosus , reactive arthritis Subjects current sign symptom may indicate active infection ( except common cold ) Subjects history chronic recurrent infection , serious lifethreatening infection within 6 month prior Baseline Visit Subjects receive live vaccination within 8 week prior Baseline Subjects know tuberculosis ( TB ) infection , high risk acquire TB infection , latent TB infection current history nontuberculous mycobacteria ( NTMB ) infection Subjects concurrent malignancy history malignancy past 5 year exclude , follow exception may include : 1 . &lt; = 3 excise ablate basal cell carcinoma skin 2 . One squamous cell carcinoma skin ( stage T1 maximum ) successfully excise , ablate ( treatment , ie , chemotherapy , apply ) , sign recurrence metastases 2 year prior Screening 3 . Actinic keratosis ( e ) 4 . Squamous cell carcinomainsitu skin successfully excise , ablate , 6 month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AS</keyword>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>Bimekizumab</keyword>
</DOC>